Latest News for: alnylam
Edit
FDA Expands Approval for Alnylam’s Drug to Treat Rare Heart Disease
The Epoch Times 22 Mar 2025
Alnylam is banking on the success of the drug, chemically called vutrisiran, to reach profitability and invest in future treatments.
Edit
Hastings Tribune
21 Mar 2025
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, ...
Hastings Tribune
21 Mar 2025
Edit
Alnylam wins FDA approval for rare heart disease drug
Business Journal 21 Mar 2025
Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major milestone — finally reaching profitability ... .
Edit
Alnylam Announces FDA Approval of AMVUTTRA� (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, ...
Business Wire 21 Mar 2025
Edit
Buy, Sell, Or Hold Alnylam Stock At $280?
Forbes 21 Mar 2025
Alnylam Pharmaceuticals (NASDAQ.ALNY) stock looks relatively expensive - making it a expensive pick to buy at its current price of around $255 ... .
Edit
Alnylam Offers Multiple Programs to Support Broad and Seamless Patient Access; Majority of Patients Expected to Pay $0 in Out-of-Pocket Costs for AMVUTTRA (Form 8-K) (Alnylam Pharmaceuticals Inc)
Public Technologies 21 Mar 2025
... with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC.
Edit
Statement of Changes in Beneficial Ownership (Form 4) (Alnylam Pharmaceuticals Inc)
Public Technologies 14 Mar 2025
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... 2 ... ALNYLAM PHARMACEUTICALS, INC ... Alnylam Pharmaceuticals Inc.
Edit
Preliminary Proxy Statement (Form PRE 14A) (Alnylam Pharmaceuticals Inc)
Public Technologies 14 Mar 2025
Edit
The Eagle-Tribune
05 Mar 2025
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
The Eagle-Tribune
05 Mar 2025
- 1